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Spatial clonal evolution leading to ibrutinib 
resistance and disease progression in chronic 
lymphocytic leukemia  
Ibrutinib has dramatically altered the therapeutic land-
scape of chronic lymphocytic leukemia (CLL) with
remarkable responses in relapsed or refractory as well as
in previously untreated CLL harboring TP53 aberra-
tions.1,2 Despite durable responses in the majority of
cases, approximately 20% of patients experience disease
progression initiated by secondary therapy resistance. In
the majority of patients progressing on ibrutinib, Bruton
tyrosine kinase (BTK) or phospholipase Cg2 (PLCG2)
resistance mutations predate the manifestation of clinical
progression by up to 15 months,3 making early and sensi-
tive detection of resistance mutations of major clinical
importance. Longitudinal studies including CLL patients
undergoing Richter transformation have shed some light
on the temporal aspects of clonal evolution processes
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Figure 1. Detailed illustration of the clinical and genetic events at ibrutinib relapse and histological features of the transformed disease. (A) Illustrated are the
main clinical and genetic events with a focus on the genetic heterogeneity observed at the time of ibrutinib relapse. (B) Morphological features and immunophe-
notype of the transformed diffuse large B-cell lymphoma. The images show hematoxylin and eosin, CD20, Ki67 and MUM1 stain (objective: 20x). ddPCR: digital
droplet PCR; FCM: flow-cytometry; FISH: Fluorescence in situ hybridization; MLPA: Multiplex ligation-dependent probe amplification; RFC: rituximab-fludarabine-
cyclophosphamid; RCVP: rituximab-cylcophosphamide-vincristine-prednisolone; RB: rituximab-bendamustine; SCT: stem cell transplantation. 
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leading to ibrutinib resistance,4-6 however, the spatial het-
erogeneity with mutations residing in various environ-
mental niches has not yet been reported in detail. Here,
we dissect an example of a CLL patient treated with ibru-
tinib displaying spatial heterogeneity in terms of the ibru-
tinib resistance mutations, and we are able to document,
for the first time, an example of ibrutinib-driven spatial
convergent evolution leading to disease progression and
transformation.
A 47-year-old man was diagnosed with a RAI stage II
CLL with unmutated IGHV gene segment and 13q dele-
tion in 90% of peripheral blood cells in August 2012.
With an active and bulky disease, the patient required
treatment and, starting in September 2012, he underwent
three lines of chemoimmunotherapy (6 cycles of ritux-
imab-fludarabine-cyclophosphamide (RFC), 5 cycles of
rituximab-cylcophosphamide-vincristine-prednisolone
(RCVP) and 5 cycles of rituximab-bendamustine (RB)),
with the last cycle of RB administered in August 2015.
The FCR treatment resulted in complete remission (CR),
with partial remission achieved in response to both
RCVP and RB regimens. The relapsed/refractory disease
was subsequently treated with ibrutinib monotherapy
(420 mg/day). Del(17p) and TP53 mutation analyses
were performed before all lines of therapies with nega-
tive results. The patient displayed a stable partial
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Figure 2. Spatiotemporal dynam-
ics of the BTK and PLCG2 muta-
tions during ibrutinib treatment.
(A) Illustrated are the fractional
abundances of the BTK p.C481S
and PLCG2 p.D993H mutations in
peripheral blood, lymph node and
circulating cell-free DNA (ccfDNA)
during the course of the disease,
as defined by digital droplet PCR
(ddPCR) assays. (B)
Representative ddPCR plots illus-
trating the different representation
of the BTK p.C481S and PLCG2
p.D993H mutations in peripheral
blood and lymph node. The muta-
tion burden was expressed as frac-
tional abundance (FA) with the FA
calculated as the ratio between
the number of mutant DNA mole-
cules and the number of mutant
plus wild type molecules. The FA
values were normalized to the CLL
cell content as defined by flow




response on ibrutinib for 21 months until the emergence
of simultaneous lymphadenomegaly and lymphocytosis
with ibrutinib resistance. Core biopsy was taken from an
enlarged lymph node, and histology examination
revealed Richter transformation to diffuse large B-cell
lymphoma (DLBCL) (Figure 1A). The clonally related
lymphoma was positive for CD20, BCL2, MUM1 and c-
MYC, and negative for CD10, CD30 and BCL6, with a
Ki67 index of 70% (Figure 1B). In addition to a common
13q deletion, 6q deletion and gain 8q were identified
exclusively in the lymph node by multiplex ligation-
dependent probe amplification (Figure 1A). The patient
was subsequently treated with venetoclax (ramping
dosage from 20 mg to 400 mg daily within 5 weeks). Due
to progression after three months, high-dose salvage
chemotherapy was administered (2 cycles of R-ESHAP:
rituximab + etoposide, cytarabine, cisplatin and methyl-
prednisolone), followed by an autologous stem cell trans-
plantation. The patient achieved complete remission
assessed by CT scan and laboratory tests, but after a
short, uneventful post-transplantational period, he
relapsed and died on day 66 after transplantation, in July
2018.
To dissect the dynamics of mechanisms leading to spa-
tial heterogeneity and ultimately conferring ibrutinib
resistance, we analysed serial samples collected at ten
different timepoints during the complete disease course
(Figure 2A). Genomic DNA was isolated from ficoll-sep-
arated peripheral blood mononuclear cells and native
lymph node tissue using the Qiagen AllPrep kit (Qiagen).
Circulating cell-free DNA (ccfDNA) was isolated with
QIAmp Circulating Nucleic Acid Kit (Qiagen) from
peripheral blood samples collected in PAXgene Blood
ccfDNA tubes (Qiagen). The fraction of tumor cells
(CD5+/CD19+ cells) was determined by flow cytometry.
Bidirectional Sanger sequencing of BTK exons 11, 15, 16,
and PLCG2 exons 12, 19, 20, 24, 27 and 30 was per-
formed on an ABI3500 genetic analyser (ThermoFisher).
Targeted ultra-deep next-generation sequencing (NGS)
analysis covering the whole coding regions of the BTK
and PLCG2 genes was performed using a TruSeq Custom
Amplicon approach on a MiSeq platform (Illumina). The
same approach was used to perform NGS analysis of the
hotspots of ATM, BCOR, BIRC3, EGR2, NOTCH1, NFK-
BIE, MYD88, SF3B1 and TP53 genes. Abundances of the
PLCG2 p.P993H and BTK p.C481S variants were quanti-
fied using custom assays on a QX200  droplet digital PCR
system (ddPCR, BioRad). The IGHV mutation status was
determined according the most recent European
Research Initiative on CLL (ERIC) recommendation.7 The
study was conducted in accordance with the Declaration
of Helsinki.
The clonal relationship between the CLL at diagnosis,
at the time of ibrutinib resistance and following Richter
transformation was confirmed by identifying an identical
IGH gene rearrangement and unmutated IGHV1-69 gene
segment in all three specimens analysed.
Sanger sequencing revealed a canonical BTK p.C481S
mutation in the peripheral blood at the time of relapse
following ibrutinib treatment. Intriguingly, a PLCG2
p.D993H mutation was detected in the lymph node spec-
imen, with the absence of the BTK p.C481S mutation
present in peripheral blood, suggesting convergent evolu-
tion in terms of the BTK and PLCG2 variants with both
commonly associated with ibrutinib resistance. To fur-
ther scrutinize this spatial heterogeneity, BTK and
PLCG2 mutations were screened by ultra-deep NGS
which confirmed the Sanger sequencing data and, in
addition to the dominant PLCG2 p.D993H variant, iden-
tified the BTK p.C481S mutation as a minor clone in the
lymph node, with the BTK p.C481S mutation remaining
the exclusive variant in the peripheral blood (Figure 1A
and 2A).
Next, we tested the presence of these mutations in the
ccfDNA isolated at the time of ibrutinib relapse using a
highly sensitive ddPCR approach. Notably, both muta-
tions were identified in the ccfDNA with a VAF of 1%
(Figure 2A), supporting previous findings that ccfDNA
may well represent a reliable source for screening
BTK/PLCG2 mutations in patients with CLL undergoing
targeted therapy.8
The scrutiny of clonal heterogeneity observed between
the peripheral blood and lymph node compartment was
extended to the most frequent mutation targets known
in CLL by performing an ultra-deep NGS analysis of the
ATM, BCOR, BIRC3, EGR2, NOTCH1, NFKBIE, MYD88,
SF3B1 and TP53 genes. In addition to the common ATM
p.Phe2393Val, NOTCH1 p.Gln2409* and SF3B1
p.Leu840Trp mutations identified in both compartments,
the BIRC3 p.Ser566fs and EGR2 p.Ala132Thr mutations
were exclusively identified in the peripheral blood (Figure
1A). The other genes showed a wild-type genotype.
Recent studies suggest that driver mutations in CLL
most likely emerge at a pre-leukemic multipotent
hematopoietic progenitor stage, with at least a fraction of
somatic mutations occurring before disease onset.9,10 The
spatial clonal heterogeneity may thus develop from a pre-
existing diverse mutation repertoire by differential selec-
tive pressure of the treatment and microenvironmental
effects in different anatomical niches. Although none of
the previous studies detected BTK or PLCG2 mutations
prior to ibrutinib therapy, in silico analyses suggest that
mutations even in these two genes may exist as early
genetic alterations within a diverse cell population.4,11
To dissect the temporal and spatial dynamics of BTK
and PLCG2 mutant subclones, ddPCR analysis was per-
formed on ten sequential peripheral blood samples col-
lected during the course of the disease and a lymph node
specimen obtained at the time of relapse, as summarized
in Figures 1A and 2A. The BTK and PLCG2 variants were
absent in the pre-ibrutinib peripheral blood sample, how-
ever, their emergence predated the clinical progression by
15 months, with the BTK and PLCG2 mutations becom-
ing detectable at month 6 on ibrutinib therapy with
minor VAFs of 0.03% and 0.003%, respectively (Figure
2A). We observed a gradual clonal expansion of these
variants in the sequential samples, demonstrating an
explicit clonal selection under the selective pressure of
the treatment. Of note, the ddPCR assay identified the
PLCG2 p.D993H mutation as a minor clone (VAF: 0.2%),
previously unseen in the peripheral blood sample by NGS
at the time of ibrutinib relapse. At this timepoint, the
PLCG2 p.D993H mutation represented a major clone
(VAF: 25%) in the lymph node sample, with a concurrent
minor BTK p.C481S clone (VAF: 5.8%) (Figure 2A). The
two subclones displayed differential sensitivity to the
subsequent venetoclax therapy, most likely conferred by
Richter transformation present in the lymph node com-
partment. In the peripheral blood, we observed a reduc-
tion of the BTK p.C481S positive subclone accompanied
by expansion of the subclone harbouring PLCG2
p.D993H which was previously dominant in the lymph
node (Figure 2A). With these dynamic changes in the sub-
clonal architecture, the disease progressed and ultimately
led to the death of the patient.
Clonal evolution is a major driving force of relapse and
progression of cancer, including haematological malig-
nancies.12 Several studies have traced the effect of treat-
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ment on temporal evolutionary trajectories of CLL in the
context of standard as well as targeted therapies and
identified profound subclonal heterogeneity and active
clonal selection in the majority of cases.6,13,14 However,
the spatial aspect of subclonal dynamics has not been
appreciated until recently. Here, we presented a unique
case of CLL, developing ibrutinib resistance via multiple
routes simultaneously, with the observed spatial hetero-
geneity leading to progression and aggressive transforma-
tion of the disease. This case highlights the importance of
genetic profiling of multiple affected sites as investiga-
tions restricted to peripheral blood may underestimate
the repertoire of clinically relevant genetic alterations
present in the patient.
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